On Tuesday, Medivation Inc (NASDAQ:MDVN)’s shares declined -7.15% to $40.54.
Medivation, Inc. ( MDVN) declared that Dr. Lynn Seely, its chief medical officer, plans to retire from her position effective October 15, 2015, after over ten years of service. She will continue as a consultant to Medivation for a period of six months, during which she will assist with the transition of her responsibilities. Mohammad Hirmand, M.D., who has been responsible for the XTANDI® (enzalutamide) prostate cancer development program, counting the pivotal clinical trials (AFFIRM and PREVAIL) which led to XTANDI’s approval for metastatic castration-resistant prostate cancer, has been promoted to interim chief medical officer and will be considered for the permanent position of chief medical officer.
Dr. Hirmand joined Medivation as senior director, clinical development in August 2007 and most recently served as senior vice president of clinical development and operations. Over the past eight years, he has played an instrumental role in advancing Medivation’s clinical trials, counting those for enzalutamide, which led to the approval of XTANDI (enzalutamide) capsules for the treatment of metastatic castration-resistant prostate cancer. Before joining Medivation, he was a senior director of clinical development at Nuvelo, Inc. (now ARCA biopharma), where he led the clinical development department comprised of clinical operations, clinical data administration and clinical sciences/medical monitor staff. Before that, he served as director of oncology development at SuperGen, Inc. (now Astex Pharmaceuticals, Inc) and as associate director of clinical research at Amgen, Inc. (formerly Tularik, Inc.), where he led clinical development efforts for Tularik’s oncology trials. Early in his career, he was a clinical scientist and manager of market development and product evaluation at Theravance Biopharma, Inc. Dr. Hirmand holds a Bachelor of Arts degree from Cornell University. Dr. Hirmand received his M.D. from Harvard Medical School.
Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients.
Alon USA Partners LP (NYSE:ALDW)’s shares dropped -0.67% to $25.15.
Alon USA Energy declared that it will release its third quarter 2015 financial results on Monday, November 2, 2015 after the market closes. In conjunction with the release, Alon has planned a conference call, which will be broadcast live over the Internet on Tuesday, November 3, 2015 at 11:00 a.m. Eastern Time (10:00 a.m. Central Time).
Alon owns 100% of the general partner and about 82% of the limited partner interests in Alon USA Partners, LP (ALDW), which owns a crude oil refinery in Big Spring, Texas with a crude oil throughput capacity of 73,000 barrels per day.
Alon USA Partners, LP refines and markets petroleum products primarily in the South Central and Southwestern regions of the United States. The company owns and operates a crude oil refinery in Big Spring, Texas with crude oil throughput capacity of 73,000 barrels per day.
At the end of Tuesday’s trade, American Electric Power Company Inc (NYSE:AEP)‘s shares dipped -1.44% to $56.63.
For the ninth successive year, American Electric Power (AEP) has been named one of the most adoption-friendly workplaces by the Dave Thomas Foundation for Adoption.
AEP provides full-time, regular employees with financial assistance of up to $3,000 per child for eligible adoption-related expenses and up to 40 hours of paid leave for new adoptive parents. Since early 2007, AEP has assisted its employees with 76 adoptions.
Information from employers nationwide was used to compile the foundation’s annual rankings of adoption-friendly workplaces. The rankings are based on the maximum amount of financial reimbursement and paid leave per adoption.
American Electric Power Company, Inc., a public utility holding company, engages in the generation, transmission, and distribution of electricity for sale to retail and wholesale customers.
Fluor Corporation (NEW) (NYSE:FLR), ended its Tuesday’s trading session with 2.27% gained, and closed at $45.55.
Fluor Corporation (FLR) will hold a conference call to review results for its third quarter ended September 30, 2015. The public is invited to listen to the conference call on Thursday, October 29, 2015, at 5:30 p.m. Eastern time with Chairman and CEO David Seaton and Chief Financial Officer Biggs Porter. Financial results will be released after the market close that day.
Fluor Corporation, through its auxiliaries, provides engineering, procurement, construction, fabrication and modularization, commissioning and maintenance, and project administration services worldwide.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
